▲ Peaking
Business
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs
2 trends tracked about this subject — the full history, oldest to newest below.
Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs
French biotech Ipsen is acquiring Kartos Therapeutics in a deal valued at up to $1.75 billion to expand its hemato-oncology pipeline.